$LGND
LIGAND PHARMACEUTICALS INC Stock $lgnd

$lgnd Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000088616317000127 Filed on November 09, 2017

Income Statement

Concept	2017 Q3	2016 Q3
Revenue	$33.38M	$21.62M
YoY Change	54.38%	22.13%
Cost Of Revenue	$2.385M	$999.0K
YoY Change	138.74%	-20.08%
Gross Profit	$30.99M	$20.62M
YoY Change	50.29%	25.34%
Gross Profit Margin	92.85%	95.38%
Selling, General & Admin	$7.030M	$6.310M
YoY Change	11.41%	26.96%
% of Gross Profit	22.68%	30.6%
Research & Development	$4.759M	$5.898M
YoY Change	-19.31%	203.24%
% of Gross Profit	15.36%	28.6%
Depreciation & Amortization	$2.000M	$2.900M
YoY Change	-31.03%	351.01%
% of Gross Profit	6.45%	14.06%
Operating Expenses	$4.759M	$5.898M
YoY Change	-19.31%	203.24%
Operating Profit	$16.49M	$5.466M
YoY Change	201.74%	-36.42%
Interest Expense	$3.386M	$3.116M
YoY Change	8.66%	6.35%
% of Operating Profit	20.53%	57.01%
Other Income/Expense, Net	-$4.422M	-$4.255M
YoY Change	3.92%	224.07%
Pretax Income	$12.07M	$1.211M
YoY Change	896.78%	-83.37%
Income Tax	$11.86M	$160.0K
% Of Pretax Income	98.29%	13.21%
Net Earnings	$67.36M	$1.051M
YoY Change	6309.32%	-99.47%
Net Earnings / Revenue	201.83%	4.86%
Basic Earnings Per Share	$3.19	$0.05
Diluted Earnings Per Share	$2.80	$0.05
COMMON SHARES
Basic Shares Outstanding	21.15M shares	20.89M shares
Diluted Shares Outstanding	24.05M shares	23.00M shares

Balance Sheet

Concept	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$202.3M	$124.1M
YoY Change	63.01%	-33.74%
Cash & Equivalents	$32.74M	$86.58M
Short-Term Investments	$169.5M	$37.50M
Other Short-Term Assets	$1.112M	$2.756M
YoY Change	-59.65%	55.09%
Inventory	$5.007M	$4.027M
Prepaid Expenses
Receivables	$12.80M	$6.600M
Other Receivables	$3.000M	$3.200M
Total Short-Term Assets	$224.2M	$140.7M
YoY Change	59.36%	-33.11%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.526M	$1.826M
YoY Change	93.1%	414.37%
Goodwill	$72.21M	$72.36M
YoY Change	-0.21%	491.26%
Intangibles	$196.6M	$207.4M
YoY Change	-5.23%	323.85%
Long-Term Investments	$5.137M	$17.34M
YoY Change	-70.37%	-45.52%
Other Assets	$2.028M	$1.744M
YoY Change	16.28%	603.23%
Total Long-Term Assets	$438.1M	$460.2M
YoY Change	-4.79%	60.9%
TOTAL ASSETS
Total Short-Term Assets	$224.2M	$140.7M
Total Long-Term Assets	$438.1M	$460.2M
Total Assets	$662.3M	$600.9M
YoY Change	10.23%	21.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.617M	$2.757M
YoY Change	31.19%	-12.28%
Accrued Expenses	$6.423M	$6.675M
YoY Change	-3.78%	60.61%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$221.6M	$210.1M
YoY Change	5.47%	16061.54%
Total Short-Term Liabilities	$231.7M	$226.1M
YoY Change	2.46%	1291.32%
LONG-TERM LIABILITIES
Long-Term Debt	$21.60M	$32.10M
YoY Change	-32.71%	-84.19%
Other Long-Term Liabilities	$695.0K	$408.0K
YoY Change	70.34%	-36.55%
Total Long-Term Liabilities	$695.0K	$408.0K
YoY Change	70.34%	-36.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$231.7M	$226.1M
Total Long-Term Liabilities	$695.0K	$408.0K
Total Liabilities	$237.6M	$230.5M
YoY Change	3.08%	0.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$393.9M	-$428.0M
YoY Change	-7.96%	-1.8%
Common Stock	$21.00K	$28.00K
YoY Change	-25.0%	40.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$403.2M	$338.3M
YoY Change
Total Liabilities & Shareholders Equity	$662.3M	$600.9M
YoY Change	10.23%	21.06%

Cashflow Statement

Concept	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	$67.36M	$1.051M
YoY Change	6309.32%	-99.47%
Depreciation, Depletion And Amortization	$2.000M	$2.900M
YoY Change	-31.03%	351.01%
Cash From Operating Activities	$22.70M	$18.50M
YoY Change	22.7%	76.19%
INVESTING ACTIVITIES
Capital Expenditures		-$800.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$51.70M	$5.800M
YoY Change	-991.38%	-122.05%
Cash From Investing Activities	-$51.50M	$5.000M
YoY Change	-1130.0%	-118.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.400M	1.600M
YoY Change	-12.5%	6.67%
NET CHANGE
Cash From Operating Activities	22.70M	18.50M
Cash From Investing Activities	-51.50M	5.000M
Cash From Financing Activities	1.400M	1.600M
Net Change In Cash	-27.40M	25.10M
YoY Change	-209.16%	-274.31%
FREE CASH FLOW
Cash From Operating Activities	$22.70M	$18.50M
Capital Expenditures		-$800.0K
Free Cash Flow		$19.30M
YoY Change		83.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2017Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1000000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2743000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000886163
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21105476	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	LIGAND PHARMACEUTICALS INC
	lgnd	Accrued Inventory Purchases AccruedInventoryPurchases	0	USD
	lgnd	Accrued Inventory Purchases AccruedInventoryPurchases	499000	USD
CY2016Q3	lgnd	Collaborative Research And Development And Other Revenues CollaborativeResearchAndDevelopmentAndOtherRevenues	1702000	USD
CY2017Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3335000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	769653000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1700000	USD
	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	0	USD
CY2017Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	793724000	USD
CY2014Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	11600000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	5331000	USD
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	15917000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	8130000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	8647000	USD
CY2016Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3540806	shares
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3522063	shares
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	255101	shares
	lgnd	Collaborative Research And Development And Other Revenues CollaborativeResearchAndDevelopmentAndOtherRevenues	15930000	USD
CY2016Q4	lgnd	Commercial License Rights CommercialLicenseRights	25821000	USD
CY2017Q3	lgnd	Commercial License Rights CommercialLicenseRights	23721000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	36000	USD
CY2016Q4	lgnd	Current Portion Of Liability For Contingent Value Rights CurrentPortionOfLiabilityForContingentValueRights	5088000	USD
CY2017Q3	lgnd	Current Portion Of Liability For Contingent Value Rights CurrentPortionOfLiabilityForContingentValueRights	86000	USD
CY2017Q1	lgnd	Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount	900000	USD
	lgnd	Equity Receivedin Repaymentof Note Receivable EquityReceivedinRepaymentofNoteReceivable	1200000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	145000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2531219	shares
CY2016Q4	us-gaap	Assets Assets	601585000	USD
CY2017Q3	us-gaap	Assets Assets	662337000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	163053000	USD
	lgnd	Equity Receivedin Repaymentof Note Receivable EquityReceivedinRepaymentofNoteReceivable	0	USD
CY2014Q3	lgnd	Exercise Priceof Convertible Bond Hedge ExercisePriceofConvertibleBondHedge	75.05
	lgnd	Increase Decreasein Fair Valueof Convertible Debt Receivableand Warrant IncreaseDecreaseinFairValueofConvertibleDebtReceivableandWarrant	464000	USD
	lgnd	Increase Decreasein Fair Valueof Convertible Debt Receivableand Warrant IncreaseDecreaseinFairValueofConvertibleDebtReceivableandWarrant	426000	USD
CY2016Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	-958000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	-2595000	USD
CY2016Q4	lgnd	Liability For Contingent Value Rights LiabilityForContingentValueRights	2916000	USD
CY2017Q3	lgnd	Liability For Contingent Value Rights LiabilityForContingentValueRights	5196000	USD
CY2017Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	-1336000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	-2302000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	224201000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	122296000	USD
CY2017Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	169520000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1564000	USD
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2518000	USD
	lgnd	Non Cash Change In Estimated Fair Value Of Contingent Value Rights NonCashChangeInEstimatedFairValueOfContingentValueRights	-2595000	USD
	lgnd	Purchasefor Commercial License Rights PurchaseforCommercialLicenseRights	0	USD
	lgnd	Threshold Business Daysfor Repaymentof Principal ThresholdBusinessDaysforRepaymentofPrincipal	P3D
	lgnd	Unsettled Repurchaseof Common Stock UnsettledRepurchaseofCommonStock	1554000	USD
	lgnd	Unsettled Repurchaseof Common Stock UnsettledRepurchaseofCommonStock	0	USD
CY2017Q3	lgnd	Working Capital Deficit WorkingCapitalDeficit	7500000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2734000	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3617000	USD
	lgnd	Collaborative Research And Development And Other Revenues CollaborativeResearchAndDevelopmentAndOtherRevenues	17500000	USD
CY2017Q3	lgnd	Collaborative Research And Development And Other Revenues CollaborativeResearchAndDevelopmentAndOtherRevenues	3780000	USD
	lgnd	Non Cash Change In Estimated Fair Value Of Contingent Value Rights NonCashChangeInEstimatedFairValueOfContingentValueRights	-2302000	USD
CY2017Q3	lgnd	Note Receivable Interestand Principal Reductionper Dollarof Value NoteReceivableInterestandPrincipalReductionperDollarofValue	0.50
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-510000	USD
	lgnd	Payments To Contingent Value Right Holders PaymentsToContingentValueRightHolders	7055000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2394000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-88000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6397000	USD
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6423000	USD
	lgnd	Payments To Contingent Value Right Holders PaymentsToContingentValueRightHolders	4998000	USD
CY2014Q3	lgnd	Paymentsfor Convertible Bond Hedges PaymentsforConvertibleBondHedges	48100000	USD
	lgnd	Proceedsfrom Repaymentof Commercial License Rights ProceedsfromRepaymentofCommercialLicenseRights	0	USD
	lgnd	Proceedsfrom Repaymentof Commercial License Rights ProceedsfromRepaymentofCommercialLicenseRights	2859000	USD
	lgnd	Purchasefor Commercial License Rights PurchaseforCommercialLicenseRights	17695000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	829000	USD
CY2017Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	634000	USD
CY2016Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	942000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	26000	USD
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	55000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1985000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	31000	USD
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	13690000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	5248000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	120758000	USD
CY2017Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	167057000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97428000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	86580000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18752000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32739000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10848000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	13987000	USD
CY2014Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	125.08
CY2014Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3264643	shares
CY2014Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3264643	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	33333333	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	33333333	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20909301	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21094836	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20909301	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21094836	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	21000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	21000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	958000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	187000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	8702000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	20158000	USD
CY2016Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	212910000	USD
CY2017Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	221557000	USD
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	999000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2674000	USD
CY2017Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2385000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3628000	USD
CY2016Q3	us-gaap	Cost Of Services Amortization CostOfServicesAmortization	2706000	USD
	us-gaap	Cost Of Services Amortization CostOfServicesAmortization	7912000	USD
CY2017Q3	us-gaap	Cost Of Services Amortization CostOfServicesAmortization	2706000	USD
	us-gaap	Cost Of Services Amortization CostOfServicesAmortization	8126000	USD
CY2016Q4	us-gaap	Debt Instrument Convertible Carrying Amount Of The Equity Component DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent	29563000	USD
CY2017Q3	us-gaap	Debt Instrument Convertible Carrying Amount Of The Equity Component DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent	21597000	USD
CY2014Q3	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	13.3251
	us-gaap	Debt Instrument Convertible Threshold Consecutive Trading Days1 DebtInstrumentConvertibleThresholdConsecutiveTradingDays1	50	D
CY2016Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	123891000	USD
CY2017Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	134939000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2017Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1075000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8322000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7581000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	3044	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	202553	shares
CY2016Q3	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	0	USD
	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	1139000	USD
CY2017Q3	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	0	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2016Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	0	USD
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	731000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9000	USD
CY2017Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	0	USD
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	0	USD
CY2016Q3	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation	0	USD
	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation	408000	USD
CY2017Q3	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation	0	USD
	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation	0	USD
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.40
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.93
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.36
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.84
CY2017Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.30
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.26
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2603000	USD
CY2017Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2479000	USD
CY2016Q4	us-gaap	Equity Method Investments EquityMethodInvestments	8345000	USD
CY2017Q3	us-gaap	Equity Method Investments EquityMethodInvestments	5137000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-183000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6550000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20858000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7032000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20904000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	72207000	USD
CY2017Q3	us-gaap	Goodwill Goodwill	72207000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1211000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	731000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	12071000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	26566000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	1051000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	759000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	8426000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	19566000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.05
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.04
CY2017Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.40
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.93
CY2016Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.05
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.03
CY2017Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.36
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.84
CY2016Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.00
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-399000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.04
CY2017Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.00
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.00
CY2016Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.00
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.03
CY2017Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.00
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.00
CY2016Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1396000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3645000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-14139000	USD
CY2017Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1019000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3350000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	160000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-28000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3079000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2649000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	411000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1909000	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-347000	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-6855000	USD
CY2016Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2017Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	47646	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	15882	shares
CY2016Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	1184092	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	1046257	shares
CY2017Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	1334357	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	1118456	shares
CY2016Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	792474	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	788106	shares
CY2017Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1019342	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	980461	shares
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	204705000	USD
CY2017Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	196578000	USD
CY2016Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	276912000	USD
CY2017Q3	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	268785000	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	3116000	USD
	us-gaap	Interest Expense InterestExpense	9172000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	2822000	USD
	us-gaap	Interest Expense InterestExpense	8625000	USD
	us-gaap	Interest Paid InterestPaid	1838000	USD
	us-gaap	Interest Paid InterestPaid	1838000	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	899000	USD
CY2017Q3	us-gaap	Interest Payable Current InterestPayableCurrent	457000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	1923000	USD
CY2017Q3	us-gaap	Inventory Net InventoryNet	5007000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	230732000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	237574000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	601585000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	662337000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	227129000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	231683000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3609000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-268000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	62258000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-56465000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-48003000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	42008000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	1051000	USD
	us-gaap	Net Income Loss NetIncomeLoss	1490000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	8426000	USD
	us-gaap	Net Income Loss NetIncomeLoss	19566000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4255000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23799000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4422000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13160000	USD
CY2016Q4	us-gaap	Notes And Loans Receivable Gross Current NotesAndLoansReceivableGrossCurrent	3207000	USD
CY2017Q3	us-gaap	Notes And Loans Receivable Gross Current NotesAndLoansReceivableGrossCurrent	3007000	USD
CY2016Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	16153000	USD
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	46257000	USD
CY2017Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	16882000	USD
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	50912000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	5466000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	24530000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	16493000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	39726000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1124000	USD
CY2017Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	778000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2175000	USD
CY2017Q3	us-gaap	Other Assets Current OtherAssetsCurrent	1112000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1744000	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2028000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	978000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	367000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	605000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	628000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	1071000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	1670000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	329000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	36000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	687000	USD
CY2017Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	695000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1215000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2107000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	755000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1117000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	1497000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	1075000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	999000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4132000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	92504000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1783000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	220000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	1776000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	371000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	73109000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	205121000	USD
	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	300000	USD
	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	200000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	113694000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	75887000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	23387000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	83390000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4608000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3864000	USD
	us-gaap	Profit Loss ProfitLoss	1490000	USD
	us-gaap	Profit Loss ProfitLoss	19566000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1819000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3526000	USD
CY2016Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	14700000	USD
CY2017Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	12816000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5898000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14813000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4759000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18254000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-431127000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-393914000	USD
CY2016Q3	us-gaap	Revenues Revenues	21619000	USD
	us-gaap	Revenues Revenues	70787000	USD
CY2017Q3	us-gaap	Revenues Revenues	33375000	USD
	us-gaap	Revenues Revenues	90638000	USD
CY2016Q3	us-gaap	Royalty Revenue RoyaltyRevenue	15698000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	39842000	USD
CY2017Q3	us-gaap	Royalty Revenue RoyaltyRevenue	21931000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	60372000	USD
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4219000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	13445000	USD
CY2017Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	7664000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	14336000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	13690000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	15917000	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.49
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.50
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.47
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.47
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.013
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.015
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.020
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.021
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y7M6D
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1754275	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1400000	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	37.49
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y9M18D
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1832961	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	42.12
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	49.41
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	31.85
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	79.74
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	102.43
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y8M12D
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	122296000	USD
CY2017Q3	us-gaap	Short Term Investments ShortTermInvestments	169520000	USD
	us-gaap	Stock Issued1 StockIssued1	77330000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	120823	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	341290000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	403166000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-271000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	628000	USD
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22997279	shares
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22997000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22742000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22742249	shares
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23551000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23551245	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23261857	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23262000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20886705	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20805604	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21070678	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21006718	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20887000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20806000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21071000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21007000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	134008	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	102282	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	79222	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	140340	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0000886163-17-000127-index-headers.html	Edgar Link	pending
0000886163-17-000127-index.html	Edgar Link	pending
0000886163-17-000127.txt	Edgar Link	pending
0000886163-17-000127-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lgnd-20170930.xml	Edgar Link	completed
lgnd-20170930.xsd	Edgar Link	pending
lgnd-20170930_cal.xml	Edgar Link	unprocessable
lgnd-20170930_def.xml	Edgar Link	unprocessable
lgnd-20170930_lab.xml	Edgar Link	unprocessable
lgnd-20170930_pre.xml	Edgar Link	unprocessable
lgnd-9301710q.htm	Edgar Link	pending
lgnd_93017exhibit311.htm	Edgar Link	pending
lgnd_93017exhibit312.htm	Edgar Link	pending
lgnd_93017exhibit321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LGND
LIGAND PHARMACEUTICALS INC Stock $lgnd

2017 Q3 Form 10-Q Financial Statement

#000088616317000127 Filed on November 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LGND LIGAND PHARMACEUTICALS INC Stock $lgnd

2017 Q3 Form 10-Q Financial Statement

#000088616317000127 Filed on November 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LGND
LIGAND PHARMACEUTICALS INC Stock $lgnd